Skip to main content
. 2017 Oct 24;7:13902. doi: 10.1038/s41598-017-12584-0

Figure 5.

Figure 5

Combining Temozolomide and lysate in a curative treatment improves median survival of glioma-bearing mice. To introduce a curative treatment strategy, lysate injection was combined with chemotherapy (temozolomide). First 20 mg/kg body weight of temozolomide was orally administered 6 times between day 5 and 16, followed by subcutaneous lysate injection at days 21, 28 and 35. The combination of temozolomide and lysate was compared to PBS treated controls and temozolomide monotherapy. One representative experiment out of two; n = 5 in the PBS control group and n = 8 in both test conditions. Statistical significance was calculated by Log-rank test, *p < 0.05; ***p < 0.001.